NeoTX is a specialty biopharmaceutical company,with a focus on research and development in oncology immunotherapy. With a strong research and development team, our strategy is to build a patented, proprietary and unique product pipeline to capitalize on technologies that NeoTX is developing independently and through collaborative partnerships and license agreements.
NeoTX is building a pipeline of differentiated cancer immunotherapies
T Cells can kill tumors but are often repressed
Our immune system is designed to kill cancer. The T cell, is the immune system’s killing machine: T cells can hunt down unhealthy cells like cancer and destroy them. Each T cell identifies a unique signature on a cell’s surface, so only the right T cell can interact with the tumor. Besides T cells specificity, the tumor can produce repressive signals, “checkpoints”, essentially inactivating the T cell.
Checkpoint inhibitors reactivate T cells
Checkpoint inhibitor therapy (“CPI”), which reactivates the T cells, enabling them to kill tumors, continues to dominate the oncology market with 2018 sales of $16BN. Since many tumors have signatures that are difficult for the immune system to identify, even when the checkpoint inhibitors reactivate the T cells, if the T cells can not recognize the tumor, then the drug will have no effect. Therefore only a relatively small fraction of patients respond to checkpoint inhibitor drugs as a monotherapy, and despite the impressive revenues, these drugs do not actually help most patients.
T cell redirection technologies can unlock the potential of checkpoint inhibitors
T cell redirection technologies (such as CAR T and BiTE) increase tumor recognition, thereby redirecting the T cells to the tumor, after they can become activated by CPIs. While CAR T and BiTE technologies have been approved in some blood-based tumors, they are only in early clinical stage development in solid tumors, as there are many hurdles that need to be overcome for them to be effective in solid tumors. CAR T suffers from serious safety concerns, manufacturing complexity and difficulties in getting the T cells through a hostile environment that surrounds the tumor. BiTE likewise has safety concerns as it can stimulate all T cells causing the immune system to go into overdrive, a condition known as cytokine release syndrome (CRS). Nevertheless, T cell redirection technologies have had high valuations including Kite Therapeutics sale to Gilead Pharmaceuticals for $12BN and Juno Therapeutics sale to Celgene for $9BN while still in phase II.
NeoTX’s Selective T cell Redirection (“STR”) Platform Overview
NeoTX’s “STR” platform represents a potential paradigm shift in T cell redirection. NeoTX’s STR drug, ANYARA, is comparatively easy to manufacture. There are early clinical observations that ANYARA can redirect the traffic of T cells into solid tumors and clinical safety has been established in 300 patients. The drug has not triggered serious CRS syndrome in patients. The drug coats the tumor with bacterial components that are easy for the T cells to identify and directs them to the tumor. Because only T cells that have the bacterial recognition signature are selectively stimulated there is less of a concern for safety
The first STR drug will enter the clinic, in combination with CPIs, in the second half of 2019. The trial will begin with a dose escalation trial designed to test its safety in combination with a CPI and will be followed by a cohort expansion in hard-to-treat patient populations.
In addition to ANYARA, NeoTX has other programs in immuno-oncology that are in research and development that seek to fill unmet medical needs.
To achieve success, NeoTX’s strategy for growth is to:
- Discover, acquire and develop technologies that modulate antigen presentation or exploit other mechanisms to enhance the immune system’s ability to attack tumors.
- Develop business partnerships with ANYARA.
- Commercialize proprietary products through corporate alliances.